Amylin Analogs

Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient intake. It was identified by Garth Cooper and colleagues in 1987 as the principal protein component of the amyloid deposits found in pancreatic islets of type 2 diabetes patients (PNAS 1987) — establishing its discovery context as both a diabetes-relevant hormone and a misfolding-prone amyloid protein. The amylin signaling axis — through heterodimeric AMY (CTR + RAMP1/2/3) receptors in hindbrain area postrema, and through additional central nervous system sites — produces glucagon suppression, gastric emptying delay, satiety, and reduced food intake. The synthetic amylin analog class began with pramlintide (Symlin, FDA-approved 2005 for type 1 and type 2 diabetes adjunct to insulin), a tri-substituted amylin analog engineered to resist amyloid aggregation while preserving receptor pharmacology. The class has expanded substantially through 2020-2026 with cagrilintide (Novo Nordisk, the long-acting weekly amylin analog at the heart of the CagriSema combination), petrelintide (Zealand Pharma, Phase 3 obesity monotherapy and combination), eloralintide (Eli Lilly LY3841136, Phase 2 obesity), and the multi-receptor amycretin (amylin + GLP-1 dual agonist, Novo Nordisk). The dominant clinical positioning has shifted from pramlintide's narrow diabetes-adjunct role to amylin-plus-GLP-1 combination therapy as a leading next-generation obesity strategy — leveraging the additive but mechanistically distinct effects of amylin (gastric emptying, satiety) and GLP-1 (insulin secretion, central appetite suppression) without the GLP-1 dose-escalation tolerability ceiling.

This page is the family-level pillar covering the amylin agonist class as a whole. For individual peptide pages with full evidence ratings, dosing, references, and trial-by-trial coverage, follow the links to each member below.

Shared mechanism

All members of the amylin family signal through the heterodimeric AMY receptor complex — calcitonin receptor (CTR) plus receptor activity-modifying proteins (RAMPs) RAMP1, RAMP2, or RAMP3 — producing the AMY1, AMY2, and AMY3 receptor subtypes respectively. The principal physiological actions are: gastric emptying delay (slowing the rate at which the stomach empties food into the small intestine, contributing to postprandial glucose smoothing and to satiety perception), glucagon suppression (in pancreatic alpha cells, opposing the postprandial glucose-raising signal), central satiety effects (through area postrema and broader hindbrain receptors that signal to higher feeding circuits), and modulation of food preference and meal termination. The mechanism is mechanistically and temporally distinct from GLP-1's insulin-secreting and central appetite-suppressing effects — which is the rationale for combining amylin and GLP-1 agents in obesity management.

Pharmacokinetic engineering across the family has progressed from short-acting native-like (pramlintide, ~50 minute plasma half-life, three-times-daily dosing) through long-acting weekly (cagrilintide, ~1 week half-life via albumin-binding fatty-acid modifications) to multi-receptor (amycretin, dual amylin + GLP-1 agonism in a single molecule) and emerging structural variants (petrelintide, eloralintide). The class avoids amyloid aggregation through selective amino-acid substitutions that disrupt the fibrillization-prone peptide backbone segments while preserving receptor binding — this engineering challenge was a substantial obstacle to early amylin drug development and continues to influence backbone design for modern long-acting analogs.

Clinical effects across the class share a common pattern: postprandial glucose smoothing through gastric emptying and glucagon-suppression effects, modest body weight reduction with monotherapy (~5-10% in larger trials), substantial body weight reduction in combination with GLP-1 agonists (~15-22% in CagriSema Phase 3 trials), generally favorable gastrointestinal tolerability that is often described as smoother than pure GLP-1 agonist therapy, and meaningful improvements in postprandial glucose excursions. The signal-to-tolerability profile of amylin agonists has been the principal argument for amylin+GLP-1 combination therapy as a next-generation obesity strategy — the additive efficacy with an arguably better tolerability ceiling than pure GLP-1 dose escalation.

History & discovery

Amylin's discovery began in the mid-1980s with Per Westermark's work on islet amyloid in type 2 diabetes pancreas tissue, but the definitive isolation and sequencing came from Garth Cooper's group at the University of Oxford with the 1987 PNAS paper (Cooper GJ et al., PMID 3317417) reporting purification and characterization of a 37-residue peptide from amyloid-rich type 2 diabetic pancreases. The peptide turned out to be co-stored with insulin in beta-cell secretory granules and co-secreted in response to glucose and nutrient stimulation — a previously unrecognized beta-cell hormone. Subsequent work characterized its biology: glucagon suppression in pancreatic alpha cells, gastric emptying delay, reduction of postprandial glucose excursions, central satiety effects through hindbrain area postrema receptors, and (relevant to its discovery context) propensity to misfold and aggregate into the amyloid fibrils characteristic of T2D pancreas pathology.

The synthetic amylin therapy era began with pramlintide (Symlin), developed by Amylin Pharmaceuticals and FDA-approved in 2005 for type 1 and type 2 diabetes as adjunct to mealtime insulin. Pramlintide is a tri-substituted amylin analog (Pro25, Pro28, Pro29 substitutions on the human amylin scaffold) engineered to resist amyloid aggregation while preserving the receptor pharmacology — solving the formulation problem that had blocked clinical use of native amylin. Pramlintide is dosed three times daily before meals via subcutaneous injection alongside insulin. Clinical adoption has been limited by the dosing burden, modest efficacy versus the GLP-1 class that emerged in parallel, and increased hypoglycemia risk when combined with insulin — pramlintide is FDA-approved and remains commercially available but is not widely prescribed in modern type 2 diabetes care.

The modern amylin analog era has been transformed by Novo Nordisk's cagrilintide and the CagriSema combination story. Cagrilintide (Novo Nordisk, AM833) is a long-acting weekly amylin analog produced by extensive backbone modification plus C20 fatty-acid attachment for albumin binding — extending the half-life from pramlintide's ~50 minutes to approximately one week. The Phase 1b cagrilintide-plus-semaglutide combination data (Lancet 2021, PMID 33894838) was the proof of concept; the Phase 2 cagrilintide monotherapy dose-finding trial (Lancet 2021, PMID 34798060) established efficacy as a stand-alone amylin agonist. The Phase 3 REDEFINE program (PMIDs 40544432, 40544433, 41328546) reported in 2025 demonstrated CagriSema's efficacy across obesity, T2D obesity, and blood pressure endpoints, positioning the combination as a leading next-generation obesity therapy. Petrelintide (Zealand Pharma) is the long-acting amylin analog underlying Roche's enicepatide+petrelintide combination Phase 2 program (first patient enrollment targeted for mid-2026), with Roche framing the combination as 'pairing a highly tolerable amylin with a strong GLP-1/GIP.' Eloralintide (Eli Lilly LY3841136) is a novel amylin receptor agonist with discovery-to-clinical-proof-of-concept reported in 2025 (PMID 41109426), positioned for obesity development. Amycretin is a multi-receptor agent (amylin + GLP-1 dual agonist) under Novo Nordisk development, blurring the line between the amylin family and the broader incretin class.

State of evidence

Evidence in this family is anchored in pramlintide's extensive type 1 and type 2 diabetes adjunct-to-insulin literature (FDA-approved 2005, two decades of real-world experience) and rapidly expanded by cagrilintide's recent monotherapy and combination data. The CagriSema Phase 3 REDEFINE program (Lau et al. NEJM 2025 and companion papers, PMIDs 40544432/40544433/41328546) reported substantial weight loss (~22% body weight reduction at 68 weeks) in adults with overweight or obesity, with separate trials in type 2 diabetes obesity and blood pressure outcomes — establishing CagriSema as a leading entry into the next-generation obesity-pharmacotherapy landscape alongside semaglutide, tirzepatide, and retatrutide. Cagrilintide monotherapy Phase 2 data (Lau et al., Lancet 2021, PMID 34798060) demonstrated meaningful weight loss as a stand-alone amylin agonist. Eloralintide Phase 2 data (Hardy et al. 2025, PMID 41109426) extended the class to a second weekly amylin agonist with comparable efficacy. Petrelintide Phase 3 data is forthcoming.

For patients, the practical takeaway is that the amylin agonist class is rapidly transitioning from a narrow pramlintide-only diabetes-adjunct role to a substantial obesity-pharmacotherapy presence, primarily through CagriSema. The combination logic is sound — amylin's gastric-emptying-and-satiety mechanism plus GLP-1's insulin-and-central-appetite mechanism produce additive efficacy with arguably better tolerability than higher-dose GLP-1 monotherapy. The choice between agents within the class will depend on indication priority (T2D vs obesity vs combination), dosing preference, payer formulary, and emerging head-to-head comparison data.

How members compare

Within the family, the principal axes are dosing interval (pramlintide three-times-daily vs cagrilintide/petrelintide/eloralintide once-weekly vs amycretin's emerging schedule) and indication breadth (pramlintide diabetes-only vs the new generation obesity-and-T2D). Receptor selectivity is broadly similar across the class (AMY1/AMY2/AMY3 agonism), with subtle differences in the relative balance that have not produced clear clinical-differentiation signals yet.

Outside the amylin family, the dominant comparison is to the GLP-1 / Incretin class — amylin and GLP-1 are mechanistically distinct but functionally complementary, and the leading obesity therapeutics will increasingly be combinations rather than pure monotherapies. CagriSema, enicepatide+petrelintide, and amycretin all reflect this combination strategy. Calcitonin (the closely related calcitonin-family peptide that shares AMY-receptor cross-reactivity) has a separate clinical role in osteoporosis and Paget's disease. The closely related 'dual amylin and calcitonin receptor agonists' (DACRAs) like KBP-336 represent an adjacent approach with similar mechanistic logic but different receptor-balance profiles.

Frequently asked questions

References

• Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patientsOriginal Research

  Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, and Reid KB, Proceedings of the National Academy of Sciences 1987. The discovery paper isolating amylin (islet amyloid polypeptide) from the amyloid-rich pancreases of type 2 diabetic patients. Foundational paper for the amylin family — established both the protein's identity and its discovery context as a beta-cell hormone with amyloid-misfolding propensity.

• Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityClinical Trial

  REDEFINE 1 — the principal Phase 3 NEJM publication of CagriSema (cagrilintide + semaglutide) in adults with obesity, demonstrating substantial body weight reduction and establishing the combination as a leading next-generation obesity therapy. Foundational reference for the CagriSema clinical case.

• Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesClinical Trial

  REDEFINE 2 — the companion Phase 3 NEJM publication of CagriSema in adults with overweight or obesity AND type 2 diabetes. Extended the obesity-only data to the diabetes-obesity population.

• CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1Clinical Trial
• Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialClinical Trial

  Lau DCW and colleagues, Lancet 2021. The cagrilintide monotherapy Phase 2 dose-finding trial — established efficacy and tolerability of cagrilintide as a stand-alone weekly amylin agonist for weight management. Set up the CagriSema Phase 3 program.

• Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trialClinical Trial

  Enebo LB and colleagues, Lancet 2021. The Phase 1b combination trial of cagrilintide + semaglutide that established the proof of concept for CagriSema. Foundational paper for the amylin+GLP-1 combination strategy.

• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of conceptClinical Trial

  The Eli Lilly amylin entry — discovery and Phase 2 clinical proof-of-concept reporting eloralintide as a second-generation weekly amylin agonist. Extends the class beyond the Novo Nordisk-led cagrilintide/CagriSema landscape.

• Cagrilintide: A Long-Acting Amylin Analog for the Treatment of ObesityReview

Related goals